Advertisement

Topics

OMEICOS Announces Formation of Inaugural Clinical Advisory Board

04:00 EST 13 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Leading Experts in Atrial Fibrillation to Complement the Company’s Key Focus Area OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention ...

Other Sources for this Article

OMEICOS Therapeutics GmbH
Dr. Robert Fischer, +49 (0) 30 9489 4810
CEO, CSO
r.fischer@omeicos.com
www.omeicos.com
or
Media:
MacDougall Biomedical Communications
Mario Brkulj or Dr. Jacob Verghese
+49 89 2424 3494 or +49 175 501 0575
mbrkulj@macbiocom.com

NEXT ARTICLE

More From BioPortfolio on "OMEICOS Announces Formation of Inaugural Clinical Advisory Board"

Advertisement
Quick Search
Advertisement
Advertisement